Matthew J. Kuhn1, Howard A. Rowley2, Cesare Colosimo3, Michael V. knopp4, Kenneth R. Maravilla5, Zoran Rumboldt6
1Radiology, University of Illinois at Peoria, Peoria, IL, United States; 2Radiology, University of Wisconsin, Madison, WI, United States; 3Radiology, University of the Sacred Heart, Rome, Italy; 4Radiology, Ohio State University, Columbus, OH, United States; 5Radiology and Surgery, University of Washington, Seattle, WA, United States; 6Radiology, Medical University of South Carolina, Charleston, SC, United States
Safety results from 5 prospective, randomized, intraindividual crossover comparison studies of gadobenate dimeglumine with other gadolinium agents for magnetic resonance imaging (MRI) of the central nervous system (CNS) are reviewed. The overall rate of adverse events in these studies was 6.0%. The type and rate of adverse events was similar after gadobenate dimeglumine and the comparator agents with no significant differences noted between agents in any study.